Köping-Höggård M, Vårum K M, Issa M, Danielsen S, Christensen B E, Stokke B T, Artursson P
Department of Pharmacy, Uppsala University, Sweden.
Gene Ther. 2004 Oct;11(19):1441-52. doi: 10.1038/sj.gt.3302312.
Nonviral gene delivery systems based on conventional high-molecular-weight chitosans are efficient after lung administration in vivo, but have poor physical properties such as aggregated shapes, low solubility at neutral pH, high viscosity at concentrations used for in vivo delivery and a slow dissociation and release of plasmid DNA, resulting in a slow onset of action. We therefore developed highly effective nonviral gene delivery systems with improved physical properties from a series of chitosan oligomers, ranging in molecular weight from 1.2 to 10 kDa. First, we established structure-property relationships with regard to polyplex formation and in vivo efficiency after lung administration to mice. In a second step, we isolated chitosan oligomers from a preferred oligomer fraction to obtain fractions, ranging from 10 to 50-mers, of more homogeneous size distributions with polydispersities ranging from 1.01 to 1.09. Polyplexes based on chitosan oligomers dissociated more easily than those of a high-molecular-weight ultrapure chitosan (UPC, approximately a 1000-mer), and released pDNA in the presence of anionic heparin. The more easily dissociated polyplexes mediated a faster onset of action and gave a higher gene expression both in 293 cells in vitro and after lung administration in vivo as compared to the more stable UPC polyplexes. Already 24 h after intratracheal administration, a 120- to 260-fold higher luciferase gene expression was observed compared to UPC in the mouse lung in vivo. The gene expression in the lung was comparable to that of PEI (respective AUCs of 2756+/-710 and 3320+/-871 pg luciferase x days/mg of total lung protein). In conclusion, a major improvement of chitosan-mediated nonviral gene delivery to the lung was obtained by using polyplexes of well-defined chitosan oligomers. Polyplexes of oligomer fractions also had superior physicochemical properties to commonly used high-molecular-weight UPC.
基于传统高分子量壳聚糖的非病毒基因递送系统在体内肺部给药后是有效的,但具有不良的物理性质,如聚集形态、在中性pH下溶解度低、用于体内递送的浓度下粘度高以及质粒DNA的解离和释放缓慢,导致起效缓慢。因此,我们从一系列分子量为1.2至10 kDa的壳聚糖低聚物开发了具有改善物理性质的高效非病毒基因递送系统。首先,我们建立了关于在对小鼠进行肺部给药后多聚体形成和体内效率的结构-性质关系。第二步,我们从优选的低聚物级分中分离壳聚糖低聚物,以获得尺寸分布更均匀、多分散性在1.01至1.09范围内的10至50聚体级分。基于壳聚糖低聚物的多聚体比高分子量超纯壳聚糖(UPC,约1000聚体)的多聚体更容易解离,并在阴离子肝素存在下释放pDNA。与更稳定的UPC多聚体相比,更容易解离的多聚体在体外293细胞中以及在体内肺部给药后介导更快的起效并产生更高的基因表达。在气管内给药后仅24小时,与体内小鼠肺中的UPC相比,观察到荧光素酶基因表达高120至260倍。肺中的基因表达与PEI相当(各自的AUC分别为2756±710和3320±871 pg荧光素酶×天/毫克总肺蛋白)。总之,通过使用定义明确的壳聚糖低聚物的多聚体,壳聚糖介导的非病毒基因递送至肺有了重大改进。低聚物级分的多聚体也具有优于常用高分子量UPC的物理化学性质。